almagate has been researched along with Innate Inflammatory Response in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrade, N; Araújo E Silva, PM; Crispim Ribeiro, J; de Moraes, MO; Fechine, FV; Savio, D | 1 |
| Agrawal, S; Christoforidis, JB; Joshi, M | 1 |
| Grabska-Liberek, I; Jamrozy-Witkowska, A; Jankowska-Lech, I; Kowalska, K; Nowosielska, A; Terelak-Borys, B | 1 |
| Kang, KN; Lee, YS | 1 |
2 review(s) available for almagate and Innate Inflammatory Response
| Article | Year |
|---|---|
Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Endophthalmitis; Humans; Infant, Newborn; Inflammation; Intravitreal Injections; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retinal Diseases; Risk; Vascular Endothelial Growth Factor A; Vitreous Body | 2013 |
RNA aptamers: a review of recent trends and applications.
Topics: Aptamers, Nucleotide; Clinical Trials as Topic; Cooperative Behavior; Humans; Inflammation; Ligands; Macular Degeneration; SELEX Aptamer Technique; Social Support; Vascular Endothelial Growth Factor A | 2013 |
2 other study(ies) available for almagate and Innate Inflammatory Response
| Article | Year |
|---|---|
Effect of Topical Instillation of Pegaptanib Sodium Upon Inflammatory Corneal Neovascularization in Rabbits.
Topics: Administration, Topical; Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Aptamers, Nucleotide; Caustics; Cornea; Corneal Injuries; Corneal Neovascularization; Disease Models, Animal; Inflammation; Instillation, Drug; Male; Neovascularization, Pathologic; Prednisolone; Rabbits; Sodium Hydroxide; Treatment Outcome; Vascular Endothelial Growth Factor A | 2021 |
[Complications of intravitreal injections--own experience].
Topics: Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Conjunctival Diseases; Diabetic Retinopathy; Endophthalmitis; Eye Diseases; Eye Hemorrhage; Female; Follow-Up Studies; Glucocorticoids; Humans; Inflammation; Intravitreal Injections; Iris Diseases; Macular Degeneration; Macular Edema; Male; Middle Aged; Ocular Hypertension; Poland; Ranibizumab; Retinal Diseases; Retinal Vein Occlusion; Retrospective Studies; Risk Factors; Triamcinolone Acetonide; Visual Acuity | 2011 |